news
Inhaled interferon beta therapy shows promise in COVID-19 trial
SNG001 diminished the risk of COVID-19 patients developing severe symptoms, reduced breathlessness and improved recovery rates.
List view / Grid view
Immunotherapy
article
Cytokine storms: a major killer in patients with severe COVID-19 infection
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
news
75 percent of nanopharmaceuticals are being developed for oncology
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
news
Chinese ABRAXANE® supply expected to be disrupted
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
news
Gilead set to acquire Forty Seven for $4.9bn later in 2020
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
news
Innovations in CAR-T therapies in APAC will make market more competitive, report highlights
Research has shown that the CAR-T therapies in development in Asia-Pacific will make the worldwide market more competitive and drive down prices.
article
Cryogel: a solid vaccine for liquid tumours
Researchers have developed a solid ‘cryogel’ vaccine that has been successful in combatting acute myeloid leukaemia in mice. How was this new formulation discovered and what potential does it have for cancer patients?
news
CRISPR-edited T cells active in patients months after initial infusion
The first US in-human trial of CRISPR-Cas9-edited T cells has concluded with no ill effects and showed that nine months later the infused cells were still active against cancer.
news
Immuno-oncology and personalised medicine to drive pharma in 2020
A survey of industry professionals states they expect immuno-oncology therapies and personalised medicines to continue to shape the pharmaceutical industry in the coming year.
news
Global neoantigen cancer vaccine market to generate $1,826.1m revenue by 2030
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
news
Cancer immunotherapy market to hit $115bn by 2023, says report
New research analysis has predicted that immunotherapy will become the oncology treatment of choice, with the market reaching $115 billion by 2023.
news
UK authorisation granted for first in-human CAR-Treg cell therapy study
Authorisation has been granted in the UK for the STEADFAST clinical study of TX200, which is the first-in-human trial to evaluate a CAR-Treg cell therapy.
news
Study shows the potential to deliver immunotherapy directly to brain tumours
New nano-immunotherapy has traversed the blood-brain barrier in mice, inducing an immune response in brain tissue surrounding tumours.
news
Imfinzi combination fails advanced lung cancer study
A late-stage clinical trial for Imfinzi and an experimental treatment has not extended the lives of patients with advanced non-small cell lung cancer.
news
Major step towards Candida auris vaccine developed
Researchers have detailed recent breakthrough experiments that successfully immunised mice against the Candida auris infection.
